SELLAS Life Sciences Group (NASDAQ:SLS) Announces Quarterly Earnings Results

SELLAS Life Sciences Group (NASDAQ:SLS) released its quarterly earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01), FiscalAI reports.

SELLAS Life Sciences Group Price Performance

Shares of SELLAS Life Sciences Group stock traded up $0.54 during trading on Wednesday, reaching $11.59. 2,180,606 shares of the company traded hands, compared to its average volume of 8,246,100. The firm has a market capitalization of $2.28 billion, a PE ratio of -50.60 and a beta of 2.48. The company has a 50 day moving average price of $11.01 and a 200-day moving average price of $7.24. SELLAS Life Sciences Group has a 1-year low of $1.39 and a 1-year high of $15.88.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Friday, July 17th. Alliance Global Partners reaffirmed a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Trading of SELLAS Life Sciences Group

Several institutional investors have recently made changes to their positions in SLS. Invesco Ltd. grew its stake in SELLAS Life Sciences Group by 6.2% in the 4th quarter. Invesco Ltd. now owns 53,293 shares of the company’s stock valued at $201,000 after purchasing an additional 3,114 shares during the period. Axxcess Wealth Management LLC boosted its stake in shares of SELLAS Life Sciences Group by 121.1% in the 4th quarter. Axxcess Wealth Management LLC now owns 35,370 shares of the company’s stock valued at $133,000 after purchasing an additional 19,370 shares in the last quarter. Beacon Pointe Advisors LLC purchased a new position in shares of SELLAS Life Sciences Group in the fourth quarter worth about $38,000. XTX Topco Ltd purchased a new stake in shares of SELLAS Life Sciences Group during the fourth quarter worth about $447,000. Finally, Millennium Management LLC grew its stake in shares of SELLAS Life Sciences Group by 341.0% in the fourth quarter. Millennium Management LLC now owns 1,387,849 shares of the company’s stock worth $5,232,000 after purchasing an additional 1,073,147 shares during the last quarter. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.